Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517259 | 0.90 | MAP4K4 (0.51) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL12518940 | 0.88 | MAP4K4 (0.49) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL13719760 | 0.88 | BTK (0.50) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL13719759 | 0.88 | BTK (0.50) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL13820019 | 0.88 | MAP4K4 (0.49) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL27814286 | 0.87 | MAP4K4 (0.49) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL12518936 | 0.85 | BTK (0.49) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL12518795 | 0.84 | MAP4K4 (0.44) | BTKMAP4K4AURKAPDPK1AURKB | |
| SCHEMBL13820031 | 0.84 | MAP4K4 (0.46) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL12517476 | 0.83 | MAP4K4 (0.54) | BTKJAK3MAP4K4AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2524917-B1 | FUSED PYRIDINE DERIVATIVES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| EP-2524917-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharmaco., Ltd. (CN) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2012-11-15 | — | — | US | disclosed |
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | GPR119, INSR, IAPP | BTK 1042/4885JAK3 566/4885MAP4K4 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.